sirolimus has been researched along with Synovitis* in 2 studies
2 other study(ies) available for sirolimus and Synovitis
| Article | Year |
|---|---|
Curcumin alleviates rheumatoid arthritis-induced inflammation and synovial hyperplasia by targeting mTOR pathway in rats.
Rheumatoid arthritis (RA) is a chronic, progressive autoimmune disease characterized by aggressive and symmetric polyarthritis. Mammalian target of rapamycin (mTOR) was reported to be a new target for RA therapy and its inhibitor rapamycin can significantly reduce the invasive force of fibroblast-like synoviocytes. Here, we determined the effect of curcumin to alleviate inflammation and synovial hyperplasia for the therapy of RA.. Collagen-induced arthritis (CIA) was developed in Wistar rats and used as a model resembling RA in humans. Rats were treated with curcumin (200 mg/kg) and the mTOR inhibitor rapamycin (2.5 mg/kg) daily for 3 weeks. Effects of the treatment on local joint, peripheral blood, and synovial hyperplasia in the pathogenesis of CIA were analyzed.. Curcumin and rapamycin significantly inhibited the redness and swelling of ankles and joints in RA rats. Curcumin inhibited the CIA-induced mTOR pathway and the RA-induced infiltration of inflammatory cells into the synovium. Curcumin and rapamycin treatment inhibited the increased levels of proinflammatory cytokines including IL-1β, TNF-α, MMP-1, and MMP-3 in CIA rats.. Our findings show that curcumin alleviates CIA-induced inflammation, synovial hyperplasia, and the other main features involved in the pathogenesis of CIA via the mTOR pathway. These results provide evidence for the anti-arthritic properties of curcumin and corroborate its potential use for the treatment of RA. Topics: Animals; Anti-Inflammatory Agents; Antirheumatic Agents; Arthritis, Experimental; Collagen Type II; Curcumin; Hyperplasia; Inflammation Mediators; Interleukin-1beta; Male; Matrix Metalloproteinase 1; Matrix Metalloproteinase 3; Protein Kinase Inhibitors; Proto-Oncogene Proteins c-akt; Rats, Wistar; Signal Transduction; Sirolimus; Synovial Membrane; Synovitis; TOR Serine-Threonine Kinases; Tumor Necrosis Factor-alpha | 2018 |
Reversible severe synovitis associated with everolimus.
Topics: Adult; Everolimus; Heart Transplantation; Humans; Immunosuppressive Agents; Intracellular Signaling Peptides and Proteins; Male; Protein Serine-Threonine Kinases; Severity of Illness Index; Sirolimus; Synovitis; TOR Serine-Threonine Kinases; Withholding Treatment | 2010 |